22.09.2014 14:10:50
|
CorMedix: Neutrolin Label Expansion Granted In EU - Quick Facts
(RTTNews) - CorMedix Inc. (CRMD) announced that TUV-SUD and The Medicinal Evaluation Board of the Netherlands has granted its request for a label expansion for Neutrolin, its catheter lock solution. The label expansion includes approval for additional indications for use in oncology patients receiving chemotherapy, IV hydration and IV medications via central venous catheters. The expansion also includes patients receiving medication and IV fluids via central venous catheters in intensive or critical care units (cardiac care unit, surgical care unit, neonatal critical care unit, and urgent care centers). An indication for use in total parenteral nutrition was also approved.
Neutrolin was initially approved in July 2013 for use in the prevention of catheter-related bloodstream infections and maintenance of catheter patency in hemodialysis patients using a tunneled, cuffed central venous catheter for vascular access.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!